Alladapt Immunotherapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.alladapt.com
Open-label Extension Study of ADP101
Phase 1
Terminated
- Conditions
- Food Allergy
- Interventions
- Biological: ADP101
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Alladapt Immunotherapeutics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05243719
- Locations
- 🇺🇸
Study Site, Seattle, Washington, United States
ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
Phase 1
Completed
- Conditions
- Food Allergy
- Interventions
- Biological: Pooled PlaceboBiological: Low dose ADP101Biological: High dose ADP101
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Alladapt Immunotherapeutics, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT04856865
- Locations
- 🇺🇸
Study Site, Seattle, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath